A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial

drug protocol number
ACE-536-B-THAL-001
drug sponsor
Celgene
drug study
Luspatercept (ACE 536)
drug trial site
King Khalid University Hospital (Riyadh)
drug status
Completed
drug phase